-
Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares
Wednesday, March 21, 2018 - 4:36pm | 369Read More...CARDIOME PHARMA CORP (NASDAQ: CRME) announced Tuesday it has agreed to divest its Canadian business to Cipher Pharmaceuticals for the U.S. dollar equivalent of $19.7 million. The Analyst Canaccord Genuity's Dewey Steadman maintains a Buy rating on Cardiome's stock with an unchanged...
-
Antares Pharma Surges Following Announcement Of CEO Change
Tuesday, January 26, 2016 - 1:21pm | 194Read More...Shares of Antares Pharma Inc (NASDAQ: ATRS), a small-cap specialty pharmaceutical company, surged higher by more than 13 percent on Tuesday after the company announced a CEO transition. Antares Pharma's Board of Directors promoted Robert Apple to the position of President and CEO from his...
-
These Four Analysts Remain Bullish On Valeant
Thursday, October 22, 2015 - 10:36am | 756Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) collapsed to a new 52-week low of $88.50 on Wednesday before slightly rebounding but have still lost more than 50 percent over the past three months.. Citron Research published what it considered to be a "smoking gun" report on Wednesday which...
-
5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm
Tuesday, September 29, 2015 - 3:27pm | 494Read More...Shibani Malhotra of Nomura is expecting the specialty pharmaceutical and generics "merger frenzy" will continue into 2016. Malhotra argued that companies with access to capital are now "more likely" to pursue deals, be it either friendly or hostile. However, Malhotra cautioned that investor...
-
Barclays Expects M&A In Specialty Pharma To Continue, Likes Valeant And Jazz
Thursday, July 9, 2015 - 8:56am | 555Read More...In a report published Wednesday, Barclays analyst Douglas Tsao detailed why he believes that M&A activity within the Specialty Pharmaceutical sector is expected to continue. According to Tsao, much of the consolidation seen in the industry has been driven by "strategic considerations" rather...
-
And The Winner From The Mylan-Perrigo Merger Is... Teva?
Thursday, April 9, 2015 - 9:16am | 270Read More...In a report published Wednesday, Citigroup analyst Liav Abraham commented on a Mylan NV (NASDAQ: MYL) and Perrigo Company plc (NYSE: PRGO) combination, noting that a bid from Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) is still possible, but challenging. According to Abraham, if Teva is...
-
JPMorgan Says Mylan Has 3 Paths To Upside
Wednesday, April 8, 2015 - 11:04am | 420Read More...In a report published Wednesday, JPMorgan analyst Chris Schott shared his thoughts on Mylan NV (NASDAQ: MYL). According to Schott, Mylan shares are showing an "increasingly attractive" set-up with solid organic growth prospects (12 percent earnings per share compounded annual growth...
